about
Functional characterization of biodegradable nanoparticles as antigen delivery system.A thermostable, chromatographically purified Ebola nano-VLP vaccine.Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinomaThe application of virus-like particles as vaccines and biological vehicles.Nanomedicine approaches to improve cancer immunotherapy.New developments in cancer vaccines.Increasing immunogenicity of cancer vaccines to improve their clinical outcome.
P2860
Q30667121-5ACB3182-7533-4AC3-912D-5A5767CCB139Q35853669-2B2543BB-89C3-4E40-B0F0-CAB7EC6B9516Q37565482-3A94FE14-BFAF-4B72-8DA0-D768A9B5446AQ38603912-8E9B5774-50F6-415E-8200-BFD1626BE08BQ39179977-706F87A5-6F73-4CF5-95EC-3898051747E1Q46502445-A6541E3A-BA14-414D-9029-60CA88C733A9Q54763767-740F2A03-025D-4C46-BB8A-6422265AFCE4
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
VLPs and particle strategies for cancer vaccines.
@en
type
label
VLPs and particle strategies for cancer vaccines.
@en
prefLabel
VLPs and particle strategies for cancer vaccines.
@en
P2860
P50
P1476
VLPs and particle strategies for cancer vaccines.
@en
P2093
Franco M Buonaguro
P2860
P304
P356
10.1586/14760584.2013.836909
P577
2013-10-01T00:00:00Z